MENLO PARK, Calif. — Grace Science, LLC, a biotechnology company founded to develop novel therapies based on the function of NGLY1, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GS-100 for the treatment of NGLY1 Deficiency. GS-100 is an...

LYON, France — Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will...

MELBOURNE, Australia and SAN FRANCISCO, Calif. — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event featuring Roy Freeman, MD (Harvard Medical School, Beth Israel Deaconess Medical...